ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1104

Quality Of Life and Burden Of Ehlers-Danlos Syndrome (EDS) Type III

Marion Geoffroy1, Christelle Guillaume1, Amélie Servettaz1, Violaine Laurant-Noel1, Christine Serratrice Sr.2, Jacques Serratrice3, Boris Bienvenu4 and Roland Jaussaud5, 1Médecine interne, maladies infectieuses, immunologie clinique, Hôpital Robert Debré. CHU de Reims, Reims, France, 2internal medicine, Foundation Hopital Saint Joseph, Marseille, France, 3Hôpital de la Timone, Marseille, France, 4Division of Internal Medicine, Centre Hospitalier Régional Universitaire de Caen, Côte de Nacre, Caen, France, Caen, France, 5Médecine interne, maladies infectieuses, immunologie clinique, CHU de Reims, REIMS, France

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Chronic pain, depression, Ehlers-Danlos syndrome, fatigue and quality of life

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Fibromyalgia, Soft Tissue Disorders and Pain II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The Ehlers-Danlos syndrome (EDS) is a clinically and genetically heterogeneous group of inherited connective tissue disorders. Hypermobility type EDS is the most common type of EDS, although commonly misdiagnosed variant of EDS. It is also the most difficult type to diagnose due to the lack of specific diagnostic laboratory tests. This type is characterized by marked joint instability, mild cutaneous involvement, chronic pain, fatigue, gastrointestinal, pelvic, neurologic and cognitive dysfunctions. The burden of delayed diagnosis and misdiagnosis, the severity of symptoms may contribute to explain.

Methods:

A questionnaire study was performed among 43 Hypermobility type EDS patients followed beetwen January and June 2013 in our center. Diagnosis was established on both the Villefranche and Brighton criteria. The following dimensions were assessed : fatigue (Fatigue severity scale, FFS), pain (visual analog scale VAS), anxiety (Hamilton score), depression (Beck depression inventory, BDI-II). Quality of life (QoL) was assessed through the French version of Short Form 36 (SF36).

Results:

Thirty five females (81%) and 8 males (19%) were included during the study period (January to June 2013). All patients had an hypermobility assessed by a Beighton score > 5. The mean age of EDS patients was 41 years. The mean age at onset was 18 years. 84% had a fatigue score ≥ 6 (FFS) and 17% reached the maximal score of 7. Of the patients included, 43 (100%) reported having pain. The mean VAS score was 67 mm. Pain was most frequently localized in neck, shoulder, hips, and forearms, and legs. 90 % of patients reported myalgia in trunk, arms and legs. Headhache, abdominal, thoracic and pelvic pains were also frequently reported (> 50%). All the patients reported anxiety. 92 % suffered from major anxiety. Depression affected 54% of patients and a quarter presented a severe depression as depicted by the BDI-II (score ≥ 27). A marked deterioration of QoL was observed in all SF36 domains.

Conclusion:

Hypermobile EDS patients are characterized by fatigue, musculoskeletal pain, anxiety and depression. All of these symptoms are major determinant of disability, which significantly influences the quality of life. Treatment of pain and fatigue should be a prominent aspect of clinical management of EDS in association with rehabilitation therapies.


Disclosure:

M. Geoffroy,
None;

C. Guillaume,
None;

A. Servettaz,
None;

V. Laurant-Noel,
None;

C. Serratrice Sr.,
None;

J. Serratrice,
None;

B. Bienvenu,
None;

R. Jaussaud,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/quality-of-life-and-burden-of-ehlers-danlos-syndrome-eds-type-iii/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology